+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Sale

Immunoprecipitation Market by Antibody (Monoclonal Antibodies, Polyclonal Antibodies), Product Type (Agarose Beads, Magnetic Beads), End User, Application - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 198 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 5533317
UP TO OFF until Dec 31st 2025
1h Free Analyst Time
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

The Immunoprecipitation Market grew from USD 1.64 billion in 2024 to USD 2.00 billion in 2025. It is expected to continue growing at a CAGR of 20.90%, reaching USD 5.14 billion by 2030.

Illuminating the Foundational Significance of Immunoprecipitation Techniques in Unraveling Protein Interactions and Driving Biotechnological Discoveries

Immunoprecipitation has become a cornerstone technique in molecular biology laboratories worldwide, enabling precise isolation and analysis of target proteins from complex biochemical mixtures. Through the selective binding of antibodies to their antigens, this assay allows scientists to capture protein complexes, investigate post-translational modifications, and dissect protein-protein interactions under physiological conditions. Since its inception, refinements in antibody engineering, bead chemistries, and detection technologies have expanded the methodological arsenal, allowing for higher sensitivity and reproducibility. Furthermore, integration with downstream analytical platforms such as mass spectrometry and next-generation sequencing has transformed immunoprecipitation into a powerful multidimensional tool that bridges immunology, proteomics, and epigenetics.

In this executive summary, we set the stage for an in-depth exploration of the immunoprecipitation landscape, detailing the key forces that are reshaping research paradigms. The following sections will shed light on technological advancements and emerging best practices, analyze the ripple effects of recent trade policy developments, and extract strategic segmentation insights across antibody types, product formats, end-user segments, and application areas. Complementing these findings, we provide regional perspectives that underscore geographical nuances, highlight leading corporate initiatives, offer actionable recommendations for decision-makers, and outline the rigorous research methodology underpinning our analysis. The conclusion ties these threads together with a forward-looking vision of the field’s evolution.

Unveiling the Major Transformational Shifts Redefining Immunoprecipitation Methodologies and Their Emerging Impact on Research Paradigms

The immunoprecipitation arena has witnessed remarkable transformations propelled by innovations in antibody design and bead technology. Advances in recombinant antibody platforms and the introduction of high-affinity monoclonal and polyclonal formats have elevated specificity and binding efficiency. Concurrently, next-generation bead substrates featuring improved surface chemistries have enhanced target capture while reducing nonspecific background. The integration of paramagnetic and superparamagnetic beads into automated workflows has further accelerated sample processing, minimizing manual handling and improving reproducibility. Moreover, the coupling of immunoprecipitation to high-resolution mass spectrometry and automated liquid handling systems has enabled proteomic and epigenetic analyses at unprecedented scale.

These methodical shifts have not only streamlined existing workflows but also opened new avenues for complex interaction studies. As researchers demand deeper insights into epigenetic modifications and post-translational landscapes, the movable boundary between immunoprecipitation and multi-omics approaches is dissolving. Consequently, workflows are becoming increasingly modular, allowing for rapid adaptation to diverse experimental objectives. This evolution underscores a broader trend toward integrated platforms that combine antibody specificity with digital data capture and analytics, setting the stage for more nuanced exploration of cellular mechanisms and accelerating translational research across academic, clinical, and industrial settings.

Exploring the Far-Reaching Consequences of United States Tariff Adjustments on Supply Chains and Reagent Accessibility for Immunoprecipitation Research

Recent adjustments to United States tariff policies have sent ripples through the global supply chain for immunoprecipitation reagents and consumables. Heightened duties on imported antibodies, bead substrates, and specialized reagents have created cost pressures for laboratory operators and reagent providers alike. Since many high-purity antibody clones and innovative bead platforms originate from international suppliers, increased import levies have extended delivery timelines and elevated pricing structures. As a result, procurement strategies have been forced to adapt, with research institutions and companies balancing budget constraints against the imperative to maintain assay performance and experimental continuity.

In response to these trade-driven headwinds, stakeholders are exploring diversified sourcing models and upstream integration of reagent manufacturing capabilities. A growing number of suppliers are investing in domestic production lines for critical antibodies and bead chemistries, while laboratories are refining inventory management protocols to mitigate the risk of stockouts. Furthermore, collaboration between regulatory agencies and industry consortia is facilitating expedited customs clearance for research-grade materials. Together, these initiatives are shaping a more resilient and responsive supply network, enabling research leaders to focus on scientific objectives without compromise.

Deriving Strategic Insights from Antibody Types Product Formats User Profiles and Application Areas Shaping Immunoprecipitation Offerings

Antibody format remains a defining dimension of immunoprecipitation strategies, with differentiated needs emerging among monoclonal and polyclonal offerings. Monoclonal antibodies, produced in mouse and rabbit hosts, are prized for their consistent specificity and batch-to-batch uniformity, making them ideal for quantitative protein pull-down assays. Meanwhile, polyclonal antibodies derived from goat and rabbit sources deliver broad epitope coverage, enhancing capture efficiency when probing diverse post-translational modifications. Understanding these distinctions has guided reagent developers in optimizing clone selection, affinity maturation processes, and antibody stabilization techniques to meet the precise requirements of varied experimental setups.

Equally critical is the choice of bead substrate and end-user profile, as well as the intended application. Agarose beads continue to serve traditional workflows with proven binding capacities, whereas magnetic bead formats-available as paramagnetic and superparamagnetic variants-are gaining favor for their compatibility with automated platforms and rapid separation kinetics. Academic and research institutes often prioritize cost-effective solutions for fundamental protein analysis, whereas contract research organizations and pharmaceutical and biotechnology companies demand scalable reagents that support high-throughput screening and clinical development workflows. Across applications, from epigenetics investigations to post-translational modification studies and broad protein interaction mapping, this layered segmentation framework drives targeted innovation and tailored service offerings.

Uncovering the Regional Dynamics of Immunoprecipitation Demand and Growth Trajectories across the Americas EMEA and Asia Pacific Markets

Across the Americas, research institutions and industrial players have established themselves at the forefront of immunoprecipitation innovation. North America’s robust funding landscape and the presence of prominent biotechnology clusters facilitate seamless collaboration between academic, clinical, and commercial entities. Laboratories in the United States leverage cutting-edge automation and data analytics tools, while collaborative networks spanning Canada and Latin America enrich the region’s capacity to address diverse scientific challenges. These synergies promote rapid method development and the transfer of novel immunoprecipitation workflows from bench to application.

In Europe, Middle East and Africa, a tapestry of regulatory frameworks and funding mechanisms creates both opportunities and complexities for reagent suppliers and end users. European research consortia often emphasize standardized protocols and cross-border harmonization, supporting high-quality reproducibility across member states. Emerging research centers in the Middle East are investing in advanced life science infrastructure, while North African institutions contribute to a growing knowledge base in protein analysis. Meanwhile, the Asia-Pacific region is experiencing exponential growth in life sciences research, driven by government initiatives, expanding manufacturing capacities, and increased private investment. From established hubs in East Asia to burgeoning capabilities in South and Southeast Asia, this dynamic environment is redefining global immunoprecipitation supply chains and scientific excellence.

Highlighting the Strategic Movements and Collaborative Innovations of Leading Companies Shaping the Future Immunoprecipitation Ecosystem

Leading reagent manufacturers and service providers in the immunoprecipitation space have intensified their focus on end-to-end solution offerings, marrying high-purity antibody production with advanced bead substrates and integrated software tools. Strategic investments in proprietary clone development and affinity screening platforms have enabled these companies to deliver bespoke reagents tailored to specialized research applications. Moreover, a trend toward modular kits that bundle optimized antibodies with pre-formulated buffers and magnetic separation hardware reflects an industry-wide drive to simplify workflows and ensure consistent experimental outcomes across diverse laboratory environments.

Collaboration has emerged as a pivotal strategy for driving innovation, with reagent suppliers forming alliances with proteomics and genomics platform developers to extend the utility of immunoprecipitation for multi-omics studies. Concurrently, contract research organizations are expanding their service portfolios to include end-to-end immunoprecipitation assays, offering clients rapid delivery of data-ready protein interaction and epigenetic profiles. This confluence of targeted R&D initiatives, strategic partnerships, and enhanced service models is propelling the field toward more integrated and user-centric solutions, positioning leading companies to capitalize on growing demand for high-precision immunoprecipitation workflows.

Formulating Proactive Strategies for Industry Leaders to Navigate Supply Challenges Technology Integration and Collaborative Research in Immunoprecipitation

To navigate ongoing supply chain constraints and evolving trade policies, industry leaders should proactively diversify their sourcing strategies by identifying alternative suppliers and establishing regional distribution hubs. Investing in localized manufacturing capabilities for critical antibody clones and bead substrates can mitigate exposure to import tariffs and logistical disruptions. Furthermore, maintaining strategic buffer inventories and collaborating closely with customs authorities will help ensure timely access to essential reagents. By aligning procurement and production plans with a comprehensive risk management framework, organizations can sustain uninterrupted research operations while optimizing cost efficiencies.

In parallel, companies and research institutions must accelerate innovation in product design and workflow automation. Integrating immunoprecipitation platforms with digital data capture and real-time analytics tools will enhance experimental throughput and reproducibility. Training laboratory personnel in advanced protocol standardization and quality control procedures is equally important to maximize assay performance. Lastly, fostering cross-disciplinary collaborations-bridging immunology, proteomics, and bioinformatics-will unlock new applications and drive adoption of immunoprecipitation as a foundational technique in precision research. These actionable steps will empower stakeholders to capitalize on emerging opportunities and maintain competitive leadership in the immunoprecipitation arena.

Detailing the Rigorous Multi Source Research Methodology Ensuring Accuracy Depth and Reliability of Immunoprecipitation Market Intelligence

The insights presented in this summary are grounded in a rigorous research methodology that integrates both secondary and primary data sources. Initial secondary research involved an extensive review of peer-reviewed journals, patent databases, technical white papers, and regulatory filings to chart the evolution of immunoprecipitation technologies and reagent portfolios. This foundational knowledge base was augmented by an analysis of company announcements, product literature, and relevant trade policies to contextualize the commercial and operational drivers influencing the field.

Primary research components included structured interviews with leading scientists at academic institutions, senior R&D executives at reagent manufacturers, and operational leaders at contract research organizations. Feedback from these stakeholders was systematically analyzed and triangulated with secondary findings to validate core trends and emerging themes. Quantitative pulse checks on reagent adoption rates and workflow integration metrics provided further rigor, while an expert advisory panel reviewed preliminary conclusions to ensure accuracy and relevancy. This comprehensive approach ensures that our strategic perspectives on immunoprecipitation are both reliable and actionable for industry decision-makers.

Concluding with a Strategic Outlook Emphasizing the Pivotal Role of Immunoprecipitation Advancements in Shaping Future Scientific Breakthroughs

The cumulative analysis underscores the transformative trajectory of immunoprecipitation as it adapts to evolving scientific demands and global trade dynamics. Technological breakthroughs in antibody engineering and bead chemistry, coupled with emerging automation solutions, are redefining workflow efficiency and experimental depth. Concurrently, revised tariff structures have prompted more robust supply chain strategies, while granular segmentation across antibody formats, product types, end-user profiles, and application areas demonstrates tailored innovation that aligns with diverse research objectives. Regional perspectives further highlight where collaborative networks and infrastructure investments are driving localized market momentum.

Looking ahead, immunoprecipitation is poised to play an ever more central role in multi-omics and precision research initiatives. Continued advancements in reagent specificity, integrated analytics, and standardization protocols will unlock new frontiers in epigenetics, proteomics, and therapeutic discovery. By leveraging the insights presented here, stakeholders can anticipate emerging opportunities, optimize strategic positioning, and drive sustainable growth. The interplay of innovation, supply resilience, and collaborative partnerships will determine the pace at which immunoprecipitation delivers its next generation of scientific breakthroughs.

Market Segmentation & Coverage

This research report categorizes to forecast the revenues and analyze trends in each of the following sub-segmentations:
  • Antibody
    • Monoclonal Antibodies
      • Mouse Monoclonal
      • Rabbit Monoclonal
    • Polyclonal Antibodies
      • Goat Polyclonal
      • Rabbit Polyclonal
  • Product Type
    • Agarose Beads
    • Magnetic Beads
      • Paramagnetic Beads
      • Superparamagnetic Beads
  • End User
    • Academic And Research Institutes
    • Contract Research Organizations
    • Pharmaceutical And Biotechnology Companies
  • Application
    • Epigenetics
    • Post Translational Modification Study
    • Protein Analysis
This research report categorizes to forecast the revenues and analyze trends in each of the following sub-regions:
  • Americas
    • United States
      • California
      • Texas
      • New York
      • Florida
      • Illinois
      • Pennsylvania
      • Ohio
    • Canada
    • Mexico
    • Brazil
    • Argentina
  • Europe, Middle East & Africa
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Spain
    • United Arab Emirates
    • Saudi Arabia
    • South Africa
    • Denmark
    • Netherlands
    • Qatar
    • Finland
    • Sweden
    • Nigeria
    • Egypt
    • Turkey
    • Israel
    • Norway
    • Poland
    • Switzerland
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Indonesia
    • Thailand
    • Philippines
    • Malaysia
    • Singapore
    • Vietnam
    • Taiwan
This research report delves into recent significant developments and analyzes trends in each of the following companies:
  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Abcam plc
  • Bio-Techne Corporation
  • QIAGEN N.V.
  • Becton, Dickinson and Company
  • PerkinElmer, Inc.
  • GenScript Biotech Corporation

 

Additional Product Information:

  • Purchase of this report includes 1 year online access with quarterly updates.
  • This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Integration of automated immunoprecipitation platforms to increase throughput and reproducibility
5.2. Development of specialized magnetic bead formulations for high specificity protein capture in complex samples
5.3. Advancements in crosslinking chemistries to improve transient protein interaction stabilization during immunoprecipitation
5.4. Emergence of dual-affinity purification tags enabling simultaneous immunoprecipitation and protein quantification
5.5. Rise of high-resolution mass spectrometry integration with immunoprecipitation workflows for proteome profiling
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Immunoprecipitation Market, by Antibody
8.1. Introduction
8.2. Monoclonal Antibodies
8.2.1. Mouse Monoclonal
8.2.2. Rabbit Monoclonal
8.3. Polyclonal Antibodies
8.3.1. Goat Polyclonal
8.3.2. Rabbit Polyclonal
9. Immunoprecipitation Market, by Product Type
9.1. Introduction
9.2. Agarose Beads
9.3. Magnetic Beads
9.3.1. Paramagnetic Beads
9.3.2. Superparamagnetic Beads
10. Immunoprecipitation Market, by End User
10.1. Introduction
10.2. Academic And Research Institutes
10.3. Contract Research Organizations
10.4. Pharmaceutical And Biotechnology Companies
11. Immunoprecipitation Market, by Application
11.1. Introduction
11.2. Epigenetics
11.3. Post Translational Modification Study
11.4. Protein Analysis
12. Americas Immunoprecipitation Market
12.1. Introduction
12.2. United States
12.3. Canada
12.4. Mexico
12.5. Brazil
12.6. Argentina
13. Europe, Middle East & Africa Immunoprecipitation Market
13.1. Introduction
13.2. United Kingdom
13.3. Germany
13.4. France
13.5. Russia
13.6. Italy
13.7. Spain
13.8. United Arab Emirates
13.9. Saudi Arabia
13.10. South Africa
13.11. Denmark
13.12. Netherlands
13.13. Qatar
13.14. Finland
13.15. Sweden
13.16. Nigeria
13.17. Egypt
13.18. Turkey
13.19. Israel
13.20. Norway
13.21. Poland
13.22. Switzerland
14. Asia-Pacific Immunoprecipitation Market
14.1. Introduction
14.2. China
14.3. India
14.4. Japan
14.5. Australia
14.6. South Korea
14.7. Indonesia
14.8. Thailand
14.9. Philippines
14.10. Malaysia
14.11. Singapore
14.12. Vietnam
14.13. Taiwan
15. Competitive Landscape
15.1. Market Share Analysis, 2024
15.2. FPNV Positioning Matrix, 2024
15.3. Competitive Analysis
15.3.1. Thermo Fisher Scientific Inc.
15.3.2. Merck KGaA
15.3.3. Danaher Corporation
15.3.4. Bio-Rad Laboratories, Inc.
15.3.5. Abcam plc
15.3.6. Bio-Techne Corporation
15.3.7. QIAGEN N.V.
15.3.8. Becton, Dickinson and Company
15.3.9. PerkinElmer, Inc.
15.3.10. GenScript Biotech Corporation
16. ResearchAI
17. ResearchStatistics
18. ResearchContacts
19. ResearchArticles
20. Appendix
List of Figures
FIGURE 1. IMMUNOPRECIPITATION MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2024 VS 2030 (%)
FIGURE 6. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
FIGURE 8. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 10. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
FIGURE 12. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 14. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 16. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. IMMUNOPRECIPITATION MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 22. IMMUNOPRECIPITATION MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 23. IMMUNOPRECIPITATION MARKET: RESEARCHAI
FIGURE 24. IMMUNOPRECIPITATION MARKET: RESEARCHSTATISTICS
FIGURE 25. IMMUNOPRECIPITATION MARKET: RESEARCHCONTACTS
FIGURE 26. IMMUNOPRECIPITATION MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. IMMUNOPRECIPITATION MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY MOUSE MONOCLONAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY MOUSE MONOCLONAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY RABBIT MONOCLONAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY RABBIT MONOCLONAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY GOAT POLYCLONAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY GOAT POLYCLONAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY RABBIT POLYCLONAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY RABBIT POLYCLONAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY AGAROSE BEADS, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY AGAROSE BEADS, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, BY REGION, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, BY REGION, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY PARAMAGNETIC BEADS, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY PARAMAGNETIC BEADS, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY SUPERPARAMAGNETIC BEADS, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY SUPERPARAMAGNETIC BEADS, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY ACADEMIC AND RESEARCH INSTITUTES, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2024 (USD MILLION)
TABLE 46. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES, BY REGION, 2025-2030 (USD MILLION)
TABLE 47. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 48. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 49. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY EPIGENETICS, BY REGION, 2018-2024 (USD MILLION)
TABLE 50. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY EPIGENETICS, BY REGION, 2025-2030 (USD MILLION)
TABLE 51. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY POST TRANSLATIONAL MODIFICATION STUDY, BY REGION, 2018-2024 (USD MILLION)
TABLE 52. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY POST TRANSLATIONAL MODIFICATION STUDY, BY REGION, 2025-2030 (USD MILLION)
TABLE 53. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY PROTEIN ANALYSIS, BY REGION, 2018-2024 (USD MILLION)
TABLE 54. GLOBAL IMMUNOPRECIPITATION MARKET SIZE, BY PROTEIN ANALYSIS, BY REGION, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 57. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 58. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 59. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 60. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 61. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 62. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 63. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 64. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 65. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 66. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 67. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 68. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 69. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 70. AMERICAS IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 71. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 72. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 73. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 74. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 75. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 76. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 77. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 78. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 79. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 80. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 81. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 82. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 83. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 84. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 85. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 86. UNITED STATES IMMUNOPRECIPITATION MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 87. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 88. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 89. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 90. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 91. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 92. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 93. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 94. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 95. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 96. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 97. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 98. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 99. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 100. CANADA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 101. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 102. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 103. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 104. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 105. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 106. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 107. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 108. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 109. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 110. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 111. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 112. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 113. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 114. MEXICO IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 115. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 116. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 117. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 118. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 119. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 120. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 121. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 122. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 123. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 124. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 125. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 126. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 127. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 128. BRAZIL IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 129. ARGENTINA IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 130. ARGENTINA IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 131. ARGENTINA IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 132. ARGENTINA IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 133. ARGENTINA IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 134. ARGENTINA IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 135. ARGENTINA IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 136. ARGENTINA IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 137. ARGENTINA IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 138. ARGENTINA IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 139. ARGENTINA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 140. ARGENTINA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 141. ARGENTINA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 142. ARGENTINA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 143. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 144. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 145. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 146. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 147. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 148. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 149. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 150. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 151. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 152. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 153. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 154. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 155. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 156. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 157. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 158. EUROPE, MIDDLE EAST & AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 159. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 160. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 161. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 162. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 163. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 164. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 165. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 166. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 167. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 168. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 169. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 170. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 171. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 172. UNITED KINGDOM IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 173. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 174. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 175. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 176. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 177. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 178. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 179. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 180. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 181. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 182. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 183. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 184. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 185. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 186. GERMANY IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 187. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 188. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 189. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 190. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 191. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 192. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 193. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 194. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 195. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 196. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 197. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 200. FRANCE IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 201. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 202. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 203. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 204. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 205. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 206. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 207. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 208. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 209. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 210. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 211. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 212. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 213. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 214. RUSSIA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 215. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 216. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 217. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 218. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 219. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 220. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 221. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 222. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 223. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 224. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 225. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 226. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 227. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 228. ITALY IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 229. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 230. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 231. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 232. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 233. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 234. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 235. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 236. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 237. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 238. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 239. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 240. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 241. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 242. SPAIN IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 243. UNITED ARAB EMIRATES IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 244. UNITED ARAB EMIRATES IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 245. UNITED ARAB EMIRATES IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 246. UNITED ARAB EMIRATES IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 247. UNITED ARAB EMIRATES IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 248. UNITED ARAB EMIRATES IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 249. UNITED ARAB EMIRATES IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 250. UNITED ARAB EMIRATES IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 251. UNITED ARAB EMIRATES IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 252. UNITED ARAB EMIRATES IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 253. UNITED ARAB EMIRATES IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 254. UNITED ARAB EMIRATES IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 255. UNITED ARAB EMIRATES IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 256. UNITED ARAB EMIRATES IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 257. SAUDI ARABIA IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 258. SAUDI ARABIA IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 259. SAUDI ARABIA IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 260. SAUDI ARABIA IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 261. SAUDI ARABIA IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 262. SAUDI ARABIA IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 263. SAUDI ARABIA IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 264. SAUDI ARABIA IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 265. SAUDI ARABIA IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 266. SAUDI ARABIA IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 267. SAUDI ARABIA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. SAUDI ARABIA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. SAUDI ARABIA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 270. SAUDI ARABIA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 271. SOUTH AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 272. SOUTH AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 273. SOUTH AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 274. SOUTH AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 275. SOUTH AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 276. SOUTH AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 277. SOUTH AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 278. SOUTH AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 279. SOUTH AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 280. SOUTH AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 281. SOUTH AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 282. SOUTH AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 283. SOUTH AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 284. SOUTH AFRICA IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 285. DENMARK IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 286. DENMARK IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 287. DENMARK IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 288. DENMARK IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 289. DENMARK IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 290. DENMARK IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 291. DENMARK IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 292. DENMARK IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 293. DENMARK IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 294. DENMARK IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 295. DENMARK IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 296. DENMARK IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 297. DENMARK IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 298. DENMARK IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 299. NETHERLANDS IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 300. NETHERLANDS IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 301. NETHERLANDS IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 302. NETHERLANDS IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 303. NETHERLANDS IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 304. NETHERLANDS IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 305. NETHERLANDS IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 306. NETHERLANDS IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 307. NETHERLANDS IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 308. NETHERLANDS IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 309. NETHERLANDS IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 310. NETHERLANDS IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 311. NETHERLANDS IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 312. NETHERLANDS IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 313. QATAR IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 314. QATAR IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 315. QATAR IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 316. QATAR IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 317. QATAR IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 318. QATAR IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 319. QATAR IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 320. QATAR IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 321. QATAR IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TABLE 322. QATAR IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2025-2030 (USD MILLION)
TABLE 323. QATAR IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 324. QATAR IMMUNOPRECIPITATION MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 325. QATAR IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
TABLE 326. QATAR IMMUNOPRECIPITATION MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
TABLE 327. FINLAND IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2018-2024 (USD MILLION)
TABLE 328. FINLAND IMMUNOPRECIPITATION MARKET SIZE, BY ANTIBODY, 2025-2030 (USD MILLION)
TABLE 329. FINLAND IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 330. FINLAND IMMUNOPRECIPITATION MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 331. FINLAND IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2018-2024 (USD MILLION)
TABLE 332. FINLAND IMMUNOPRECIPITATION MARKET SIZE, BY POLYCLONAL ANTIBODIES, 2025-2030 (USD MILLION)
TABLE 333. FINLAND IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2018-2024 (USD MILLION)
TABLE 334. FINLAND IMMUNOPRECIPITATION MARKET SIZE, BY PRODUCT TYPE, 2025-2030 (USD MILLION)
TABLE 335. FINLAND IMMUNOPRECIPITATION MARKET SIZE, BY MAGNETIC BEADS, 2018-2024 (USD MILLION)
TAB

Samples

Loading
LOADING...

Companies Mentioned

  • Thermo Fisher Scientific Inc.
  • Merck KGaA
  • Danaher Corporation
  • Bio-Rad Laboratories, Inc.
  • Abcam plc
  • Bio-Techne Corporation
  • QIAGEN N.V.
  • Becton, Dickinson and Company
  • PerkinElmer, Inc.
  • GenScript Biotech Corporation

Table Information